業聚醫療(06929.HK):2023年經調整年內利潤同比增長73.1%至4620萬美元
格隆匯3月7日丨業聚醫療(06929.HK)發佈截至2023年12月31日止年度年度業績公吿,2023年,經濟從COVID-19疫情影響中逐漸復甦,但全球經濟逆境繼續令營商環境面臨挑戰。2023年,美國聯邦儲備局通過加息對抗通脹,導致美元走強,進而影響集團以美元計值的收入增長勢頭。儘管如此,集團仍錄得收入1.539億美元,較去年增長12.5%。撇除外匯影響,同比收入增長率將為15.4%。大幅增長主要是由於銷量由2022年的約120萬件增至2023年的140萬件。尤其是,PCI球囊及PTA球囊的收入分別同比增長12.1%及29.0%至1.154億美元及1470萬美元。
毛利因在日本及美國市場平均售價較高的產品銷量增加而增長15.2%至約1.065億美元。公司擁有人應占年內利潤為4510萬美元,較2022年的1850萬美元增長143.8%。2023年的淨利率為29.3%,同比增長15.8個百分點。2023年的每股基本盈利為5.45美仙(2022年︰3.17美仙)。
經調整年內利潤(非香港財務報吿準則計量指標)(不包括上市開支、可轉換可贖回優先股的利息回撥及以股份為基礎的薪酬開支等若干非現金及一次性項目)同比增長73.1%至約4620萬美元。從經調整年內利潤(非香港財務報吿準則計量指標)剔除融資收入淨額及美元商品票據公允值變動的核心經營利潤為3440萬美元,同比增長34.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.